FDA Passes on Novartis Heart Failure Drug Drug Discovery & Development Novartis announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for RLX030 (serelaxin) for the treatment of acute heart failure (AHF), stating that ... |
